Perceptive Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-3,708,705
Closed -$104M – 136
2019
Q3
$104M Buy
3,708,705
+155,645
+4% +$2.52M 2.79% 10
2019
Q2
$50.1M Buy
3,553,060
+427,209
+14% +$4.06M 1.15% 21
2019
Q1
$27.8M Hold
3,125,851
– – 0.78% 33
2018
Q4
$23.7M Hold
3,125,851
– – 0.9% 31
2018
Q3
$65.5M Hold
3,125,851
– – 1.75% 16
2018
Q2
$93.5M Buy
3,125,851
+344,874
+12% +$9.39M 2.45% 9
2018
Q1
$75.4M Buy
2,780,977
+971,962
+54% +$29.1M 2.11% 11
2017
Q4
$52.1M Buy
1,809,015
+55,000
+3% +$1.51M 1.73% 15
2017
Q3
$42.6M Buy
1,754,015
+47,516
+3% +$1.13M 1.64% 14
2017
Q2
$38M Buy
+1,706,499
New +$35.9M 1.91% 13

Perceptive Advisors's DOVA Position: Q4 2019 in Review

Perceptive Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 3,708,705 shares — an estimated $104M sold.

Perceptive Advisors first reported a position in DOVA in Q2 2017 and held it in 10 quarters. The position peaked at $104M in Q3 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • Perceptive Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Perceptive Advisors sold 3,708,705 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $104M.
  • Perceptive Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 10 quarters.
  • Perceptive Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $104M in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Perceptive Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.